The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy.
D'Andrea
M
M
Nosotti
L
L
Pimpinelli
F
F
Dessanti
M L
ML
Paviglianiti
A
A
Miglioresi
L
L
Morrone
A
A
Petti
M C
MC
D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy*; D018890:Chemoprevention; D064420:Drug-Related Side Effects and Adverse Reactions; D006509:Hepatitis B / Q000188:drug therapy*; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000276:immunology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy; D012189:Retrospective Studies
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D019259:Lamivudine